Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.70)
# 3,433
Out of 4,670 analysts
89
Total ratings
22.22%
Success rate
-31.49%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Reiterates: Buy | $30 | $6.04 | +396.69% | 4 | Nov 19, 2024 | |
| EYEN Eyenovia | Downgrades: Neutral | $12 → $2 | $0.11 | +1,758.74% | 14 | Nov 18, 2024 | |
| KOD Kodiak Sciences | Reiterates: Neutral | $3 | $6.19 | -51.53% | 3 | Nov 15, 2024 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $7 | $4.70 | +48.94% | 3 | Nov 15, 2024 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $7.79 | +362.13% | 15 | Nov 14, 2024 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $2.60 | +361.54% | 2 | Nov 13, 2024 | |
| OPTN OptiNose | Reiterates: Buy | $5 | $0.48 | +941.67% | 5 | Nov 13, 2024 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $30 | $12.49 | +140.19% | 4 | Nov 12, 2024 | |
| LENZ LENZ Therapeutics | Reiterates: Buy | $38 | $35.50 | +7.04% | 3 | Nov 7, 2024 | |
| OPT Opthea | Maintains: Buy | $14 → $12 | $3.16 | +279.76% | 4 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.19 | +958.20% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.86 | +7.53% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $9.34 | +199.79% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.85 | +106.19% | 10 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.14 | +777.19% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $230.43 | -87.85% | 1 | Aug 22, 2023 |
Adverum Biotechnologies
Nov 19, 2024
Reiterates: Buy
Price Target: $30
Current: $6.04
Upside: +396.69%
Eyenovia
Nov 18, 2024
Downgrades: Neutral
Price Target: $12 → $2
Current: $0.11
Upside: +1,758.74%
Kodiak Sciences
Nov 15, 2024
Reiterates: Neutral
Price Target: $3
Current: $6.19
Upside: -51.53%
DiaMedica Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $7
Current: $4.70
Upside: +48.94%
4D Molecular Therapeutics
Nov 14, 2024
Reiterates: Buy
Price Target: $36
Current: $7.79
Upside: +362.13%
FibroBiologics
Nov 13, 2024
Reiterates: Buy
Price Target: $12
Current: $2.60
Upside: +361.54%
OptiNose
Nov 13, 2024
Reiterates: Buy
Price Target: $5
Current: $0.48
Upside: +941.67%
Mineralys Therapeutics
Nov 12, 2024
Reiterates: Buy
Price Target: $30
Current: $12.49
Upside: +140.19%
LENZ Therapeutics
Nov 7, 2024
Reiterates: Buy
Price Target: $38
Current: $35.50
Upside: +7.04%
Opthea
Sep 3, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $3.16
Upside: +279.76%
Aug 15, 2024
Reiterates: Neutral
Price Target: $2
Current: $0.19
Upside: +958.20%
Aug 12, 2024
Reiterates: Neutral
Price Target: $2
Current: $1.86
Upside: +7.53%
Aug 12, 2024
Reiterates: Buy
Price Target: $28
Current: $9.34
Upside: +199.79%
Aug 9, 2024
Reiterates: Buy
Price Target: $10
Current: $4.85
Upside: +106.19%
Nov 14, 2023
Reiterates: Buy
Price Target: $10
Current: $1.14
Upside: +777.19%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $230.43
Upside: -87.85%